Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment
|
|
- Kerry Davidson
- 5 years ago
- Views:
Transcription
1 Xie et al. World Journal of Surgical Oncology (2017) 15:209 DOI /s RESEARCH Open Access Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment Yunqing Xie 1, Lijie Huang 1, Luchuan Chen 2, Xiaowei Lin 1, Li Chen 1 and Qiuhong Zheng 1* Abstract Background: Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients. These patients have a poor 5-year survival rate of 5% or less. Furthermore, a large dose of chemotherapy can produce adverse side effects and severe toxicity. Therefore, this retrospective study aimed to evaluate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell infusion as an adjuvant therapy in patients with advanced colorectal cancer combined with first-line treatment. Methods: A total of 142 patients with stage III/IV colorectal carcinoma who had been treated with first-line therapy were included in this study. Among these patients, 71 patients received first-line treatment only (non-dc-cik group), while the other 71 patients who had similar demographic and clinical characteristics received a DC-CIK cell infusion combined with first-line treatment (DC-CIK group). These patients were followed up until August Data were analyzed by Kaplan-Meier and Cox regression. Results: Our results showed that the 5-year overall survival (OS) rate for the DC-CIK group versus the non-dc-cik group was 41.3 versus 19.4% (p = 0.001) and the 5-year progression-free survival (PFS) rate for the DC-CIK group versus the non- DC-CIK group was 57.4 versus 33.6% (p = 0.022). Conclusions: Our results showed that patients with advanced colorectal cancer might benefit from DC-CIK immunotherapy combined with first-line therapy by significantly prolonging 5-year OS and PFS. Keywords: Dendritic cells, Cytokine-induced killer cells, Adjuvant immunotherapy, Colorectal cancer Background Colorectal cancer (CRC) is ranked the third leading malignancy and one of the leading causes of cancer-related deaths worldwide [1]. Over 20% of CRC patients have metastatic disease at the time of diagnosis [2]. In such advanced patients, who have a poor 5-year survival rate of 5% or less, surgical resection combined with adjuvant chemotherapy and/or radiotherapy has been recommended as the gold standard of treatment [3 7]. However, severe adverse side effects of such therapies limit the use of chemotherapy and radiotherapy in advanced CRC patients * Correspondence: niuniu @hotmail.com 1 Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Medical University Cancer Hospital, Fuzhou , China Full list of author information is available at the end of the article [8, 9]. In the past decade, cell-based immunotherapy has been reported to improve the clinical outcomes by altering tumor immune responses, improving prognosis and overall survival rates, and the quality of life in cancer patients [10 12]. Furthermore, it may minimize the presence of residual or resistant tumor cells after surgery, radiotherapy, and chemotherapy. However, studies of dendritic cellcytokine-induced killer (DC-CIK) cells remain in preliminary stages, and the conclusion as to whether DC-CIK treatment in patients with distant metastatic disease is still poorly understood. It has been previously reported that lymphocyteactivated killer (LAK) cells achieved clinical anti-tumor effects [13]. However, LAK cells have not been widely developed due to their inefficient proliferation and low The Author(s) Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Xie et al. World Journal of Surgical Oncology (2017) 15:209 Page 2 of 6 anti-tumor activity. These hurdles were overcome by the identification of cytokine-induced killer (CIK) cells in 2005, which are rapidly proliferative and possess powerful anti-tumor activity and minimal toxicity [14]. CIK cells are a group of heterogeneous cells, characteristically expressing the T cell marker CD3 and natural killer (NK) cell markers CD56 or CD16. It has been demonstrated that the administration of CIK cells can improve overall survival rates and quality of life for malignant patients [15, 16]. In 2010, dendritic cells (DCs) were approved for treating metastatic prostate cancer by the FDA [17]. DCs are the most potent antigen-presenting cells regulating and maintaining T cell responses in order to provide protective anti-tumor immunity. Moreover, many studies have indicated that DCs may enhance the function of CIK by significantly improving proliferation and tumor-specific activity of CIK cells [18]. Indeed, the clinical benefits of DC-CIK have been reported in patients with solid tumors [14, 19, 20]. A few studies examining the effectiveness of DC-CIK/ CIK immunotherapy for colorectal cancer have been reported [21, 22]. In the past studies, we have achieved promising findings demonstrating DC-CIK cell therapy as an adjuvant therapy for colorectal cancer and shown significant improvement in 3-year overall survival rate and disease-free survival rate [23, 24]. Wang et al. [25] showed DC-CIK immunotherapy significantly improved 3-year disease-free survival (DFS) in patients combined with chemotherapy. Gao et al. [21] also indicated that CRC are more sensitive to DC-CIK therapy than GC, and DFS and overall survival (OS) were both significantly prolonged in patients in the DC-CIK treatment group. However, few studies have focused on advanced CRC patients. In the present study, we reviewed 142 advanced colorectal cancer treated with conventional or adjuvant DC-CIK therapy and analyzed their respective 1-, 3-, and 5-year OS rates and progression-free survival (PFS) rates. The purpose of our study was to investigate whether advanced colorectal cancer could benefit from DC-CIK combined with first-line treatments. Methods Patient selection A retrospective analysis was carried out on the medical records of colorectal cancer patients in our hospital from January 1, 2006, to August 31, The inclusion criteria were as follows: (1) patients were pathologically diagnosed with colorectal cancer at stages III IV according to the International Union Against Cancer s (UICC 2002) classification based on ptnm system; (2) all patients received standard first-line treatment including surgical resection, adjuvant chemotherapy, and/or radiotherapy; and (3) another cohort of patients received at least two cycles of DC-CIK immunotherapy. Exclusion criteria were as follows: (1) patients who did not receive standard first-line treatment and (2) patients who were not in advanced stages (III IV stages). After review, 142 patients who met the described criteria were enrolled in this study for further analysis (Table 1). Among them, 71 patients received DC-CIK treatment (DC-CIK group), whereas the other 71 patients without DC-CIK treatment were used as the control group for comparisons. First-line treatment All enrolled CRC patients underwent primary tumor resection and postoperative FOLFIRI chemotherapy with or without radiotherapy. The FOLFIRI [irinotecan (CPT- 11), leucovorin (LV), and 5-FU] regimen consisted of CPT-11 intravenous infusion (80 mg/m 2 ) on day 1, intravenous LV infusion (400 mg/m 2 ) on day 1, and intravenous bolus injection (0.4 g/m 2 ) and 46-h infusion (2.4 g/m 2 ) of 5-FU on day 1 and day 2. This regimen was repeated every 2 weeks. DC and CIK cell generation Peripheral blood mononuclear cells (PBMCs) were separated from a 50-mL peripheral blood sample from each patient in the DC-CIK group by Ficoll-Paque density gradient centrifugation. PBMCs ( cells/ml) were plated onto six-well dishes (BD). Non-adherent cells were collected after 2 h of incubation at 37 C under 5% CO 2. Adherent cells were cultured in GT-T551 medium containing granulocyte-macrophage colony-stimulating factor (GM-CSF; 100 ng/ml; Amoytop) and interleukin- 4 (IL-4; 50 ng/ml; Amoytop). The medium was replaced every 2 days. WT1 antigen (Miltenyi, UK) was then added to the medium at day 5 to a final concentration of 100 g/ml and cocultured with DCs for an additional 24 h. Non-adherent cells were collected for CIK cell preparation. Cells were resuspended at a concentration of cells/ml with GT-T551 medium containing interferongamma (IFN-γ; 1000 U/mL; Novo protein) and cultured in 75-cm 2 culture flasks at 37 C under 5% CO 2.Cellswere treated with 1000 U/mL IL-2 (Sihuanpharm) and 50 ng/ml anti-cd3 monoclonal antibody (Takara) after 24 h. Cell density was readjusted to cells/ml by using fresh mediumcontaining500u/mlil-2fromday2today10. During the culture period, matured DCs were isolated by flow cytometry (Beckman) via DC-specific markers CD83, CD80, CD86, and HLA-DR (BD). Matured DCs were harvested and mixed with CIK cells at a ratio of 1:10 at day 7. On day 10, the co-cultured (DC-CIK) cells were examined by flow cytometry for CIK cell-specific markers with antibodies against CD3, CD8, and CD56 (Beckman).
3 Xie et al. World Journal of Surgical Oncology (2017) 15:209 Page 3 of 6 Table 1 Clinicopathological characteristics of 142 patients Characteristics Total (n = 142) Control (n = 71) DC-CIK (n = 71) p value Sex, male/female 79/63 40/31 39/ Age (years), mean ± SD 55.4 ± ± ± KPS, mean ± SD 70.4 ± ± ± Adenocarcinoma Well differentiated Moderately differentiated Poorly differentiated Unknown TNM stage (III/IV) 98/54 41/30 47/ FOLFIRI chemotherapy cycles > Radiotherapy (yes/no) 49/93 22/49 27/ DC-CIK treatment and follow-up DC-CIK cell-based treatment was combined with firstline treatments. Our study was approved by the Ethics Committee of Fujian Provincial Tumor Hospital (IRB ). All 71 patients received at least two cycles of DC-CIK cells and signed informed consent. Before transfusion, bacterial contamination and endotoxin levels were tested and were < 0.06 EU within 48 h. DC-CIK cells were then harvested and resuspended in normal salt solution and administered via intravenous infusion during intervals of chemotherapy twice a day for 4 days. The treatment protocol is shown in Fig. 1. Four transfusions were defined as one cycle. Patients received a total of cells at each cycle. The interval of every cycle was at least 2 weeks. All patients were followed up after discharge, including clinic or telephone contact every 3 months for the first 2 years, 6 months for the next 3 years, and yearly thereafter from the fifth year. In this study, the followup deadline was August Follow-up included blood routine examination, colonoscopy every 6 months, CEA levels, and chest/abdominal CT scans every 6 12 months. In the DC-CIK group, lymphocyte subsets were determined before the start of every cycle of DC-CIK therapy. PET-CT was performed if tumor recurrence or metastases were suspected. Quality of life (QOL) of patients was evaluated according to the Karnofsky scores. Statistical analysis SPSS 16.0 software was used for analyzing data. Data was showed in mean ± SD. The postoperative survival rate was compared with the Kaplan-Meier method. Clinically different characteristics between the DC-CIK group and the control group before and after DC-CIK therapy were compared by Student s t test. The Cox proportional hazard regression test was used for multivariate analysis. p < 0.05 was set as statistical significance. Results Baseline characteristics of patients A total of 142 patients with histologically confirmed colorectal carcinoma were enrolled in this study, 71 in the DC-CIK group and 71 in the control group. All patients were at stages III and IV. The clinical characteristics of these two groups are described in Table 1. There were no significant differences in demographic and clinical characteristics Fig. 1 Illustration of the DC-CIK cell treatment protocol
4 Xie et al. World Journal of Surgical Oncology (2017) 15:209 Page 4 of 6 between these two groups. Despite DC-CIK transfusion, treatment strategies and medical management were similar in these two groups. Side effects of DC-CIK cell transfusion During and after DC-CIK cell transfusion, six patients (8%) suffered from mild fever, chills, and fatigue; three also developed a headache; and one developed chest tightness and hypotension. All of them recovered after symptomatic treatment. There were no adverse reactions such as anaphylaxis. No patients presented with abnormal liver function tests (LFTs) or kidney function. Quality-of-life assessment Quality of life in DC-CIK-treated patients had the KPS score of ± 8.53 compared to that of the control of ± 7.82, which is statistically significant (p < 0.05). Comparison of the effectiveness in clinic In the median 76-month follow-up period of time, the median survival time of the patients in the DC-CIK group and non-dc-cik group was 32 months (95%CI months) and 17 months (95%CI months), respectively, which was statistically significant (p < 0.001). We then subsequently analyzed the 1, 3, and 5-year progression-free survival rates, which were 85.3, 64.1, and 57.4%, respectively, in the DC-CIK group, whereas in the non-dc-cik group were 65.0, 44.3, and 33.6%, respectively (p = 0.017; Fig. 2). Furthermore, the 1, 3, and 5-year overall survival rates were 84.5, 46.0, and 41.3%, respectively, in the DC-CIK group compared to 65.7, 23.4, and 19.4%, respectively, in the non-dc-cik group (p = 0.001; Fig. 3). Our data indicated that DC- CIK cells as an adjuvant therapy combined with firstline treatment could significantly reduce mortality and recurrence for advanced colorectal carcinoma. Fig. 2 Kaplan-Meier estimate for progression-free survival (PFS) of patients Fig. 3 Kaplan-Meier estimate for overall survival (OS) of patients Discussion The present retrospective study of advanced CRC patients revealed several important findings. Firstly, DC- CIK cell adjuvant transfusion resulted in significantly prolonged 5-year OS rates compared to that of the control group. Secondly, the 5-year PFS rates were significantly improved. Finally, the 1- and 3-year OS and PFS rates in the DC-CIK group were higher than those in the control group. These results suggested that DC-CIK cell treatment, combined with first-line therapy, is an effective therapeutic strategy for treatment of advanced colorectal cancer. DC-CIK cell treatment has been an established technique and is now widely used in cancer patients. Previous clinical studies have provided strong evidence supporting the efficacy of DC-CIK immunotherapy combined with chemotherapy and radiotherapy. Zhao et al. [26] showed that the GP regimen combined with DC- CIK immunotherapy would reduce postoperative tumor recurrence and prolonging the survival time of patients with NSCLC. Ma et al. [27] dedicated that CIK cell therapy demonstrated a significant superiority in prolonging the median overall survival, PFS, DCR, ORR and QoL of HCC patients. Other studies of gastric cancer [28], advanced renal cancer [29], and metastatic nasopharyngeal carcinoma [30] demonstrated that DC- CIK cell infusions could improve outcomes of patients. In our study, we selected 142 advanced CRC patients for evaluating the impact of adjuvant DC-CIK cell infusion, in particular in reference to 5-year OS and 5-year PFS rates, when combined with first-line routine therapy. Our results, consistent with previous studies in other advanced cancers, indicated that adjuvant DC-CIK cells could prolong 5-year OS and PFS rates for advanced CRC patients [26 30]. The 5-year OS rate of the control group in our study was similar to that in Gao et al. s [21] showing 19.4 vs. 15% of effects, while Zhu et al. [31]
5 Xie et al. World Journal of Surgical Oncology (2017) 15:209 Page 5 of 6 suggested that CIK cells could prolong DFS but not OS rates for resected CRCs. Although the 3- and 5-year OS and PFS rates in our present DC-CIK group were lower than our other previously published studies in earlier staged CRC patients [23, 24], we have achieved promising results in advanced CRC patients and improved outcomes without adverse side effects. It was also shown that DC-CIK adjuvant transfusion therapy is safe and tolerated in advanced CRC patients. Immunosuppression may be apparent in patients after surgery and chemotherapy, especially in advanced cancer patients. Moreover, DCs obtained from such patients may be dysfunctional and more likely to induce tolerance or non-productive T cell responses because of lost expression of antigens or MHC molecules in advanced patients [32]. Therefore, the clinical benefits of DC-CIK cells may be due to their strong anti-tumor activities through immumodulation [33]. DC-CIK cells not only eradicated residual tumor cells but also enhanced immune surveillance capacity of host cells by producing pro-inflammatory cytokines, such as IL-2 and IFN-γ to prevent or delay tumor recurrence [34, 35]. However, the responsible mechanisms for these clinical benefits remain to be elucidated. While some objective clinical benefits have been demonstrated in patients with advanced or metastatic CRC, more studies are warranted. Firstly, due to the retrospective nature limitations, a well-designed prospective study should be carried out to examine these results further. Secondly, combined therapies may be optimized by comparison with other recent cell-based therapeutic studies. Indeed, it has been reported that chemotherapy and/or radiotherapy before cell transfusion can enhance anti-tumor effects in previous clinical studies [36]. Moreover, a recent study reported cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) and programmed death ligand1 (PD-1) may play key roles in inhibiting T cell activation during cell therapies [37]. Currently, we are combining adoptive transfer of T cells with PD1 and CTLA-4 blockade after inductive chemotherapy and/or radiotherapy in a similar manner. In the future, we believe that several alternative modalities may improve immunotherapy with traditional therapies and ultimately change patient outcomes in advanced CRC cancer patients. Conclusion In summary, DC-CIK cell adjuvant transfusion resulted in significantly prolonged 5-year OS rates compared to that of the control group. Secondly, the 5-year PFS rates were significantly improved; the 1- and 3-year OS and PFS rates in the DC-CIK group were higher than those in the control group. These results suggested that DC- CIK cell treatment, combined with first-line therapy, is an effective therapeutic strategy for treatment of advanced colorectal cancer. Acknowledgements Not applicable. Funding This study was supported in part by grants from the Natural Science Foundation of Fujian Province (#2016J01514) and the National Natural Science Foundation of China (# ). Availability of data and materials All data generated or analyzed during this study are included in this published article. Authors contributions YQ conceived and designed the study and wrote the paper; LJ analyzed and provided the patient statistical data; LC performed the histological examination; XW and LI accomplished the cell culture; QH reviewed and edited the manuscript. All authors read and approved the final manuscript. Ethics approval and consent to participate This study was approved by the ethics committee of Fujian Medical University cancer Hospital and was carried out in accordance with the Declaration of Helsinki of the World Medical Association. All enrolled patients provided written informed consent. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author details 1 Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Medical University Cancer Hospital, Fuzhou , China. 2 Department of Abdominal Surgery, Fujian Medical University Cancer Hospital, Fuzhou , China. Received: 19 June 2017 Accepted: 15 November 2017 References 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2013;63: Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375: Damin DC, Lazzaron AR. Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options. World J Gastroenterol. 2014;20: Ke TW, Liao YM, Chiang HC, Chang SC, Wang PH, Chen YY, et al. Effectiveness of neoadjuvant concurrent chemoradiotherapy versus up-front proctectomy in clinical stage II III rectal cancer: a population-based study. Asia Pac J Clin Oncol. 2016;12(2):e Laurent M, Paillaud E, Tournigand C, Caillet P, Le Thuaut A, Lagrange JL, et al. Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist. 2014;19: Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27: Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2012;62: Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Investig. 2008;26: Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78: Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, et al. Developments in clinical cell therapy. Cytotherapy. 2010;12:425 8.
6 Xie et al. World Journal of Surgical Oncology (2017) 15:209 Page 6 of Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7: Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25: Oliver A,., Canton L,., Montanari M: GM-CSF plus IL- 2 administration associated with multiple autologous LAK refusion can induce a major cytogenetic response in early relapsed CML after autologous transplantation: a case report. Bone Marrow Transplant 1998;21: Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137: Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K, et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother. 2012;61: Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3: Frohlich MW. Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol. 2012;39: Su X, Zhang L, Jin L, Ye J, Guan Z, Chen R. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokineinduced killer cells. J Clin Immunol. 2010;30: Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006;12: Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, et al. Dendritic cellactivated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11: Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 2014;9:e Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, et al. Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int. 2014;2014: Wei ZQ, Yang JW, Chen LC, Zheng QH, Ying MG. A retrospective analysis of postsurgical treatment for rectal cancer by chemotherapy and radiotherapy combined with dendritic cells. Fujian YikeDaxue Xuebao. 2009;43: Ying MG, Wei ZQ, Yang JW, Chen LC, Zheng QH. Retrospective analysis of pos-operative chemo-radiotherapy combined with DC-CIK in the treatment of patients with colorectal cancer. ShiyongAizheng Zazhi. 2010;25: Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, et al. Combination of chemotherapy and immunotherapy for colon cancer in China: a metaanalysis. World J Gastroenterol. 2014;20: Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014;7: Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1: Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61: Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014;14: Li JJ, MF G, Pan K, Liu LZ, Zhang H, Shen WX, et al. Autologous cytokineinduced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35: Zhu Y, Zhang H, Li Y, Bai J, Liu L, Liu Y, et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother. 2013;62: Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48: Swartz MA. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res. 2014;2: Schlom J. Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm. 2012;27: Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11: Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26: Drake CG. Combination immunotherapy approaches. Ann Oncol. 2012; 23(Suppl 8):viii41 6. Submit your next manuscript to BioMed Central and we will help you at every step: We accept pre-submission inquiries Our selector tool helps you to find the most relevant journal We provide round the clock customer support Convenient online submission Thorough peer review Inclusion in PubMed and all major indexing services Maximum visibility for your research Submit your manuscript at
Department of Hematopoietic Stem Cell Transplantation, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing , China
Med J Chin PLA, Vol. 41, No. 10, October 1, 2016 827 [ ] (DC) (CIK) 27 (PBMC) DC CIK 7 9 11 13 DC 11 13 CIK 3 27 DC-CIK 37% 85% 2 81.5% CD3 + CD4 + CD8 CD3 + CD4 CD8 + CD3 + CD19 CD3 CD19 + CD3 CD16 +
More informationReview Article The efficacy of combination of chemotherapy and cytokine-induced killer cells therapy for soft tissue cancer: a meta-analysis
Int J Clin Exp Med 2017;10(6):8666-8676 www.ijcem.com /ISSN:1940-5901/IJCEM0034132 Review Article The efficacy of combination of chemotherapy and cytokine-induced killer cells therapy for soft tissue cancer:
More informationEnhanced antitumor effects and improved immune status of dendritic cell and cytokine induced killer cell infusion in advanced cancer patients
MOLECULAR AND CLINICAL ONCOLOGY 7: 903-910, 2017 Enhanced antitumor effects and improved immune status of dendritic cell and cytokine induced killer cell infusion in advanced cancer patients FENG CHEN,
More informationEffectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1063-1067, 2015 Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer BIN CHEN 1*, LIFEN LIU
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationAdoptive Immunotherapy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCorresponding author: X.J. Wang
Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma L. Yan, M. Wu, N. Ba, L.J. Wang, H.Q.
More informationClinical Study Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
Hindawi Immunology Research Volume 2017, Article ID 1092507, 8 pages https://doi.org/10.1155/2017/1092507 Clinical Study Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationCirculating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics Jie Zhang, Jing Gao, Yanyan
More informationMcAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells
Effects of McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells X.C. Wei, D.D. Yang, X.R. Han, Y.A. Zhao, Y.C. Li, L.J. Zhang and J.J. Wang Institute of hematological research,
More informationA study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.
Biomedical Research 2018; 29 (2): 365-370 ISSN 0970-938X www.biomedres.info A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationDoes serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study
Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More information0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no
2003 12 10 83 23 Natl Med J China, December 10,2003,Vol 83, No. 23 2049 (CIK ), T, CIK 13 (PBMC),,4 7 10 13 15 ;CIK, (DC1) (CD2),CD3 + CD8 +, CD3 + CD56 +, CD25 +, 3315 % 1011 % 717 % 218 %1213 % 415 %,3616
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationRESEARCH ARTICLE. Abstract. Introduction
RESEARCH ARTICLE Continuous DC-CIK Infusions Restore CD8 + Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments Yan-Jie
More informationratio in patients treated by sorafenib alone decreased after treatment (P<0.05), while CD 8
Int J Clin Exp Med 2016;9(2):4625-4629 www.ijcem.com /ISSN:1940-5901/IJCEM0015836 Original Article Effect of sorafenib combined with CIK cell treatment on immunity and adverse events in patients with late-stage
More informationCT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series
Malalagama et al. Cancer Imaging (2017) 17:17 DOI 10.1186/s40644-017-0119-3 CASE SERIES CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series Geethal N. Malalagama
More informationOriginal Article Tissue expression level of lncrna UCA1 is a prognostic biomarker for colorectal cancer
Int J Clin Exp Pathol 2016;9(4):4241-4246 www.ijcep.com /ISSN:1936-2625/IJCEP0012296 Original Article Tissue expression level of lncrna UCA1 is a prognostic biomarker for colorectal cancer Hong Jiang,
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationAdjuvant dendritic cells vaccine combined with cytokineinduced-killer cell therapy after renal cell carcinoma surgery
JBUON 2015; 20(2): 505-513 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant dendritic cells vaccine combined with cytokineinduced-killer
More informationAdoptive Immunotherapy
Medical Policy Manual Medicine, Policy No. 42 Adoptive Immunotherapy Next Review: October 2018 Last Review: March 2018 Effective: April 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationDiagnostic and prognostic value of CEA, CA19 9, AFP and CA125 for early gastric cancer
Feng et al. BMC Cancer (2017) 17:737 DOI 10.1186/s12885-017-3738-y RESEARCH ARTICLE Open Access Diagnostic and prognostic value of CEA, CA19 9, AFP and CA125 for early gastric cancer Fan Feng 1, Yangzi
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationAnalysis of the prognosis of patients with testicular seminoma
ONCOLOGY LETTERS 11: 1361-1366, 2016 Analysis of the prognosis of patients with testicular seminoma WEI DONG 1, WANG GANG 1, MIAOMIAO LIU 2 and HONGZHEN ZHANG 2 1 Department of Urology; 2 Department of
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationVaccine Therapy for Cancer
Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence
More informationCombined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer
He et al. BMC Gastroenterology 2013, 13:87 RESEARCH ARTICLE Open Access Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer Chao-Zhu He 1,2, Kun-He Zhang
More informationExpression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5525-5530 Expression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer Y.-X. SHI, B.-L. YE, B.-R. HU, X.-J.
More informationHongfei Gao 1, Lijun Yuan 2 and Yimin Han 1*
Gao et al. World Journal of Surgical Oncology (2016) 14:168 DOI 10.1186/s12957-016-0930-5 RESEARCH Open Access Comparisons of the survival time of patients with ovarian cancer adopting postoperative chemotherapy
More informationOncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date
MP 8.01.03 Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationTakashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6
Yagisawa et al. Renal Replacement Therapy (2016) 2:68 DOI 10.1186/s41100-016-0080-9 POSITION STATEMENT Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry
More informationThe clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population
Zhang et al. BMC Cancer (2019) 19:22 https://doi.org/10.1186/s12885-018-5147-2 RESEARCH ARTICLE Open Access The clinicopathological features and treatment modalities associated with survival of neuroendocrine
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationCircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 3713-3718 CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer N. LIU 1, J. ZHANG 1, L.-Y. ZHANG 1, L.
More informationTreatment and prognosis of type B2 thymoma
Song et al. World Journal of Surgical Oncology 2014, 12:291 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Treatment and prognosis of type B2 thymoma Zhengbo Song 1,2, Xiangyu Jin 1,2 and Yiping
More informationHui Zhu, 1 Xuejing Yang, 2 Jiali Li, 1 Yanjie Ren, 2 Tianyu Zhang, 2 Chunze Zhang, 3 Jintai Zhang, 4 Jing Li, 1 and Yan Pang 1. 1.
BioMed Research International, Article ID 603871, 5 pages http://dx.doi.org/10.1155/2014/603871 Clinical Study Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More informationClinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer
Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer T.Y. Sun, W. Yan, C.M. Yang, L.F. Zhang, H.L. Tang, Y. Chen, H.X. Hu and X. Wei General Surgery
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationOriginal Article Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer
Int J Clin Exp Med 2015;8(8):14527-14537 www.ijcem.com /ISSN:1940-5901/IJCEM0009633 Original Article Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment
More informationAdvanced duodenal carcinoma: Chemotherapy efficacy and analysis of prognostic factors
Oncology and Translational Medicine DOI 10.1007/s10330-015-0094-8 February 2016, Vol. 2, No. 1, P16 P20 ORIGINAL ARTICLE Advanced duodenal carcinoma: Chemotherapy efficacy and analysis of prognostic factors
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationCytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
Experimental Hematology & Oncology METHODOLOGY Open Access Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety Yue Ma 1, Ying-Chun Xu 1, Lei Tang
More informationAdoptive Immunotherapy
Adoptive Immunotherapy Policy Number: 8.01.01 Last Review: 6/2018 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Adoptive
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More information290 Clin Oncol Cancer Res (2009) 6: DOI /s
290 Clin Oncol Cancer Res (2009) 6: 290-295 DOI 10.1007/s11805-009-0290-9 Analysis of Prognostic Factors of Esophageal and Gastric Cardiac Carcinoma Patients after Radical Surgery Using Cox Proportional
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationClinical Trials for Liver and Pancreatic Cancer in Taiwan
Japan - Taiwan Joint Symposium on Medical Oncology Session 6 Hepatobiliary and pancreatic cancers Clinical Trials for Liver and Pancreatic Cancer in Taiwan Li-Tzong Chen 1,2 *, Jacqueline Whang-Peng 1,3
More informationInhibition of cisplatin-resistant tumor cells on activated CD4+ T cells in ovarian cancer and its mechanism
Pharmaceutical Inhibition of cisplatin-resistant tumor cells on activated CD4+ T cells in ovarian cancer and its mechanism Objective: To investigate the inhibition of cisplatin-resistant tumor cells on
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationCancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006
Chinese Journal of Cancer Original Article Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006 Xiao-Pan Li 1, Guang-Wen Cao 2, Qiao
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationPrognostic significance of nemo like kinase in nasopharyngeal carcinoma
MOLECULAR MEDICINE REPORTS 10: 131-136, 2014 Prognostic significance of nemo like kinase in nasopharyngeal carcinoma SIZE CHEN 1,2*, ZHIJIAN MA 3*, XUEMEI CHEN 4 and JIREN ZHANG 1 1 Department of Oncology,
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationManagement Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study
Management Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study Henaine AM; Chahine G; Massoud M; Salameh P; Awada S; Lahoud N; El
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationPublished: Address correspondence to Vidal-Jove Joan:
Oncothermia Journal 7:111-114 (2013) Complete responses after hyperthermic ablation by ultrasound guided high intensity focused ultrasound (USgHIFU) plus cystemic chemotherapy (SC) for locally advanced
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationSubdural hemorrhages in acute lymphoblastic leukemia: case report and literature review
Yin et al. Chinese Neurosurgical Journal (2016) 2:25 DOI 10.1186/s41016-016-0045-4 CHINESE NEUROSURGICAL SOCIETY CASE REPORT CHINESE MEDICAL ASSOCIATION Subdural hemorrhages in acute lymphoblastic leukemia:
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationAdoptive Immunotherapy
Adoptive Immunotherapy Policy Number: 8.01.01 Last Review: 10/2018 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Adoptive
More informationInvestigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma
Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma Q. Zhang 1, L.Y. Lv 1, B.J. Li 1, J. Zhang 1 and F. Wei 2 1 Department of Orthopaedics,
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationFocused Ultrasound and Cancer Immunotherapy
Focused Ultrasound and Cancer Immunotherapy Overview A number of therapeutic modalities including radiation, radiofrequency and laser-induced heating, cryoablation, and focused ultrasound have been shown
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationComparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists
Original Article Comparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists Lixin Jiang, Zengwu Yao, Yifei Zhang, Jinchen
More informationEffect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus
Original papers Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus Hongyang Lu 1,2,A,B,D, Fajun Xie 2,B, Zhiyu Huang 2,B, Jing Qin 2,C,E, Na Han
More informationRESEARCH ARTICLE. Jia-Xiang Ye 1, Xia Liang 2, Jian Wei 3, Jing Zhou 3, Yu Liao 3, Yu-Lei Lu 3, Xia-Quan Tang 3, An-Yu Wang 3, Yong Tang 1 * Abstract
DOI:10.22034/APJCP.2018.19.1.115 Treatment Compliance of Stage II IVB Nasopharyngeal Carcinoma RESEARCH ARTICLE Editorial Process: Submission:08/06/2017 Acceptance:12/02/2017 Compliance with National Guidelines
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationThe updated incidences and mortalities of major cancers in China, 2011
DOI 10.1186/s40880-015-0042-6 REVIEW Open Access The updated incidences and mortalities of major cancers in China, 2011 Wanqing Chen *, Rongshou Zheng, Hongmei Zeng and Siwei Zhang Abstract Introduction:
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationOriginal Article Effect of immunotherapy on the immune function and survival of patients after colon cancer surgery
Int J Clin Exp Med 2016;9(2):1780-1786 www.ijcem.com /ISSN:1940-5901/IJCEM0006179 Original Article Effect of immunotherapy on the immune function and survival of patients after colon cancer surgery Derong
More information